Table 4.
Impact of HY-score at 3 months post-HCT on clinical outcomes in multivariate analyses
| HY score* | cGVHD | NRM | Relapse | OS | ||||
|---|---|---|---|---|---|---|---|---|
| HR† (95% CI) | P | HR† (95% CI) | P | HR† (95% CI) | P | HR† (95% CI) | P | |
| As a continuous variable | 1.37 (1.19-1.59) | <.0001 | 1.66 (1.17-2.35) | .0043 | 0.83 (0.66-1.04) | .11 | 1.11 (0.94-1.31) | .2 |
| As a group variable | ||||||||
| 0 | 1 | Ref. | 1 | Ref. | 1 | Ref. | 1 | Ref. |
| 1 | 1.11 (0.55-2.24) | .77 | 0.73 (0.09-5.96) | .77 | 0.97 (0.45-2.09) | .94 | 0.92 (0.40-2.11) | .85 |
| 2-3 | 2.19 (1.17-4.11) | .014 | 13.4 (1.99-89.7) | .0076 | 0.42 (0.17-1.02) | .06 | 0.62 (0.24-1.62) | .33 |
| 4-6 | 5.00 (2.30-10.9) | <.0001 | 20.0 (2.70-148) | .0034 | 0.56 (0.18-1.73) | .32 | 1.78 (0.79-4.01) | .16 |
Ref., reference.
*
HY score is the cumulative number of HY-Abs detected 3 mo post-HCT.
†
HRs are shown after adjusting for age of patient and donor, disease, disease risk, CMV serostatus, donor types, cell sources, usage of total body irradiation, usage of anti-thymocyte globulin, and grade of aGVHD.